David Crockett, MD
Internal Medicine · Omaha, NENPI 1801107636
Payments from drug & device makers
Across 83 payments — averaging $9895.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$470K
- Aadi Bioscience, Inc.$146K
- Merck$90K
- Amgen$53K
- Puma Biotechnology, Inc.$43K
- Eli Lilly$11K
- plus $9K from 19 others
Across 1 payment — averaging $123.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $469,726 |
| Aadi Bioscience, Inc. | 12 | $146,252 |
| Merck | 11 | $89,769 |
| Amgen | 10 | $52,989 |
| Puma Biotechnology, Inc. | 4 | $43,064 |
| Eli Lilly | 1 | $10,925 |
| Genentech, Inc. | 1 | $6,500 |
| Hoffmann-la Roche Limited | 3 | $1,494 |
| Aimmune Therapeutics, Inc. | 1 | $152 |
| AbbVie | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Sanofi | 2 | $43 |
| Genentech USA, Inc. | 2 | $40 |
| Pfizer | 2 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $28 |
| Acrotech Biopharma Inc. | 2 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Advanced Accelerator Applications | 1 | $9 |
How this compares
$821,327 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
- Mridula KrishnanOmaha$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.